Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, Xi ^a   Mu, Xin ^b   Huang, Ou ^a   Xie, Zuoquan ^c   Jiang, Min ^a   Geng, Meiyu ^c   Shen, Kunwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER 703 PROTEIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84883159846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072053     Document Type: Article

References (65)

1. Tran B, Bedard PL, (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13: 221.
2. Chia S, Bryce C, Gelmon K, (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365: 1665-1666.
3. Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, et al. (2008) Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112: 1437-1444.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
5. Dixon JM, Jackson J, Renshaw L, Miller WR, (2003) Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. The Journal of Steroid Biochemistry and Molecular Biology 86: 295-299.
6. Mauriac L, (2002) Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Annals of Oncology 13: 293-298.
7. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, et al. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16: 5222-5232.
8. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
9. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108-5116.
10. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17: 6012-6020.
11. Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, et al. (2012) Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 460: 251-259.
12. Muller BM, Brase JC, Haufe F, Weber KE, Budzies J, et al. (2012) Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol 65: 660-662.
13. Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, et al. (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24: 640-647.
14. Osborne CK, Schiff R, (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247.
15. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331S-336S.
16. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935.
17. Levin ER, Pietras RJ, (2008) Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108: 351-361.
18. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, et al. (2009) Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and-resistant breast cancer cells. Steroids 74: 586-594.
19. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, et al. (2005) Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18: 250-259.
20. Baselga J, Campone M, Piccart M, Burris HA, (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529.
21. Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, et al. (2012) Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 323: 77-87.
22. Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, et al. (2011) ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 3: 153-166.
23. Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, et al. (2011) ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3: 167-180.
24. Slorach EM, Chou J, Werb Z, (2011) Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev 25: 471-484.
25. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
26. Spellman P, Gray J, (2011) A new treasure in the breast cancer gene hunt. Nat Med 17: 422-423.
27. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
28. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, et al. (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
29. Eriksson N, Benton GM, Do CB, Kiefer AK, Mountain JL, et al. (2012) Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet 13: 53.
30. Dawson SJ, Rueda OM, Aparicio S, Caldas C, (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32: 617-628.
31. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
32. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146.
33. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, et al. (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121: 53-64.
34. Bazarov AV, Yaswen P, (2011) Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors. Breast Cancer Res 13: 308.
35. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146.
36. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, et al. (2013) Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 137: 397-406.
37. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, et al. (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11: 5319-5328.
38. Beaver JA, Park BH, (2012) The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 8: 651-657.
39. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, et al. (2013) Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer.
40. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476.
41. Wu RC, Smith CL, O'Malley BW, (2005) Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev 26: 393-399.
42. Schiff R, Massarweh S, Shou J, Osborne CK, (2003) Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9: 447S-454S.
43. Vyhlidal C, Samudio I, Kladde MP, Safe S, (2000) Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol 24: 329-338.
44. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D, (2007) Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 13: 7029-7036.
45. Lopez-Tarruella S, Schiff R, (2007) The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res 13: 6921-6925.
46. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, et al. (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17: 575-588.
47. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV, (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23: 7721-7735.
48. Guo S, Sonenshein GE, (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 24: 8681-8690.
49. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, et al. (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12: R40.
50. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 97: 9042-9046.
51. Chu IM, Hengst L, Slingerland JM, (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
52. Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, et al. (2003) p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 63: 4322-4326.
53. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL, (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 12Suppl 1: S47-59.
54. Lange CA, Yee D, (2011) Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 18: C19-24.
55. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, et al. (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117: 218-228.
56. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
57. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, et al. (2012) Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 72: 5048-5059.
58. Guo S, Li Y, Tong Q, Gu F, Zhu T, et al. (2012) deltaEF1 Down-Regulates ER-alpha Expression and Confers Tamoxifen Resistance in Breast Cancer. PLoS One 7: e52380.
59. Pan X, Zhou T, Tai YH, Wang C, Zhao J, et al. (2011) Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med 17: 708-714.
60. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, et al. (2011) Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 17: 715-719.
61. Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, et al. (2012) LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 132: 537-544.
62. Jin K, Kong X, Shah T, Penet MF, Wildes F, et al. (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A 109: 2736-2741.
63. Arpino G, Green SJ, Allred DC, Lew D, Martino S, et al. (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676.
64. Jeong H, Ryu YJ, An J, Lee Y, Kim A, (2012) Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60: E87-95.
65. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.